BioNTech To Initiate Phase 1/2 Clinical Trial Of MRNA-based Mpox Vaccine Program BNT166
BioNTech SE (BNTX) and the Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday a strategic partnership to advance mRNA-based vaccine candidates with the development of BNT166 for the prevention of mpox (formerly monkeypox) mpox, caused by a member of the Orthopoxvirus viral family, is an infectious disease that can lead to severe, life-threatening complications. CEPI will provide funding of up […]
Read more